AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics reported a Q2 net loss of $8.2 million, widening from a $6.5 million loss in the prior year, driven by increased R&D spending as it advances its pipeline. The company ended the quarter with $79.9 million in cash and investments, projecting a runway into 2029 under its current operating plan. Operationally, AN2 is advancing three Phase 2 programs: expanding a global PV trial for epetraborole, ongoing enrollment in an M.
Key figures
- Net loss
- $8.2 million
- Cash runway
- into 2029
- Ga expenses
- $2.9 million
- Rd expenses
- $6.0 million
- Cash position
- $79.9 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.